About ZIVO Bioscience, Inc.
https://www.zivobioscience.comZIVO Bioscience, Inc., a research and development company, engages in licensing and selling natural bioactive ingredients derived from its proprietary algae cultures to animal, human, and dietary supplement and medical food manufacturers.
CEO
John Bernard Payne
Compensation Summary
(Year 2022)
Salary $397,754
Option Awards $449,999
Incentive Plan Pay $175,000
Total Compensation $1,022,753
Industry Biotechnology
Sector Healthcare
Went public December 15, 2003
Full time employees 7
Price Target
Target High $0
Target Low $0
Target Median $0
Target Consensus $0
Market Cap $164234
52w High $0.04
52w Low $0.04
P/E 0
Volume 3.00K
Outstanding Shares 3.73M
About ZIVO Bioscience, Inc.
https://www.zivobioscience.comZIVO Bioscience, Inc., a research and development company, engages in licensing and selling natural bioactive ingredients derived from its proprietary algae cultures to animal, human, and dietary supplement and medical food manufacturers.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $65.63K ▲ | $1.04M ▼ | $-1.03M ▲ | -1.57K% ▲ | $-0.27 ▲ | $-1.02M ▲ |
| Q2-2025 | $53.4K ▲ | $1.65M ▼ | $-1.64M ▲ | -3.07K% ▼ | $-0.43 ▲ | $-1.63M ▲ |
| Q1-2025 | $0 ▼ | $4.21M ▲ | $-4.21M ▼ | 0% ▲ | $-1.12 ▼ | $-4.21M ▼ |
| Q4-2024 | $90K ▲ | $1.62M ▼ | $-1.6M ▲ | -1.78K% ▲ | $-0.47 ▲ | $-1.6M ▲ |
| Q3-2024 | $31.5K | $2.27M | $-2.27M | -7.2K% | $-0.67 | $-2.26M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $57.22K ▲ | $559.45K ▼ | $231.79K ▼ | $-3.29M ▼ |
| Q2-2025 | $9.82K ▼ | $703.33K ▼ | $3.24M ▲ | $-2.54M ▼ |
| Q1-2025 | $517.19K ▼ | $1.33M ▼ | $2.95M ▲ | $-1.62M ▼ |
| Q4-2024 | $1.54M ▲ | $1.64M ▲ | $2.16M ▼ | $-514.9K ▲ |
| Q3-2024 | $159.4K | $495.59K | $2.58M | $-2.08M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-1.03M ▲ | $-266.56K ▲ | $0 | $313.95K ▲ | $47.4K ▲ | $-266.56K ▲ |
| Q2-2025 | $-1.64M ▲ | $-476.41K ▲ | $0 | $-30.96K ▼ | $-507.37K ▲ | $-476.41K ▲ |
| Q1-2025 | $-4.21M ▼ | $-1.43M ▼ | $0 | $404.99K ▼ | $-1.03M ▼ | $-1.43M ▼ |
| Q4-2024 | $-1.6M ▲ | $-905.72K ▲ | $0 | $2.29M ▲ | $1.38M ▲ | $-905.72K ▲ |
| Q3-2024 | $-2.27M | $-1.09M | $0 | $1.24M | $156.94K | $-1.09M |
CEO
John Bernard Payne
Compensation Summary
(Year 2022)
Salary $397,754
Option Awards $449,999
Incentive Plan Pay $175,000
Total Compensation $1,022,753
Industry Biotechnology
Sector Healthcare
Went public December 15, 2003
Full time employees 7
Price Target
Target High $0
Target Low $0
Target Median $0
Target Consensus $0